Open-label, non-comparative study of combination use of ONO-4538 and ONO-7703 in patients with advanced or metastatic solid tumors
Latest Information Update: 13 Aug 2022
At a glance
- Drugs Binimetinib (Primary) ; Nivolumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Ono Pharmaceutical
- 24 Jul 2018 Status changed from not yet recruiting to recruiting.
- 23 Feb 2018 New trial record